In 2023, the sales for antihypertensive medicine in Norway were at a certain value (unspecified). The forecast from 2024 to 2028 shows a steady increase, reaching 2.2 USD PPP Per Capita from 2.1 USD PPP Per Capita. The year-on-year variation from 2023 to 2024 indicates a growth trend, continuing from 2024 onwards.
Key points:
- 2024: 2.1 USD PPP Per Capita
- 2025: 2.2 USD PPP Per Capita
- 2026: 2.2 USD PPP Per Capita
- 2027: 2.2 USD PPP Per Capita
- 2028: 2.2 USD PPP Per Capita
The average CAGR over these 5 forecasted years reflects a minor but consistent growth.
Future trends to watch for include:
- Advancements in antihypertensive medication technology.
- Legislative changes impacting pharmaceutical pricing and insurance reimbursement.
- Demographics shifts and healthcare policy improvements.
